Sponsor-Investigators

H. Scott Boswell

BTCRC-HEM17-092

Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092

Status

Closed

Cancer Types

Leukemia

Locations